Asset profile
Glecirasib
Small molecule
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2029-09-30.
NCT05002270: The study was a small, non-randomized, open-label trial without a comparator, evaluating safety, tumor response, and duration of response. Because results are not posted and the design cannot provide a controlled comparison, it offers limited evidence for glecirasib.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
69 competitors in this universe: 9 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Glecirasib: this drug | Phase 3 | Small molecule | KRAS G12C | ||
| Sotorasib | Approved | Small molecule | KRAS G12C | ||
| Calderasib | Phase 3 | Small molecule | KRAS G12C | ||
| Divarasib | Phase 3 | Small molecule | KRAS G12C | ||
| Fulzerasib | Phase 3 | Small molecule | KRAS G12C | ||
| JMKX001899 | Phase 3 | Small molecule | KRAS G12C | ||
| Elironrasib | Phase 1/2 | Small molecule | KRAS G12C | ||
| FMC-376 | Phase 1/2 | Small molecule | KRAS G12C | ||
| BBO-8520 | Phase 1 | Small molecule | KRAS G12C | ||
| HBI-2438 | Phase 1 | Small molecule | KRAS G12C | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A |
…and 54 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
March 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (2)
2029 (1)
September 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.